Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients

NCT00543569 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00543569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00543569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2008
Completion date
February 28, 2011
Enrollment
323 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplantation